Overview

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company